In breast cancer asymptomatic patients after HER2-targeted treatment with medium or high baseline cardiotoxicity risk, a follow-up echocardiogram and clinical assessment should be considered 3–6 months and 12 months after the final dose [3, 6, 20, 51]. The gene discussed is ERBB2; the disease is breast carcinoma.